{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:41:12Z","timestamp":1769222472248,"version":"3.49.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parasitic infections are often perceived as diseases of low-resource countries, yet they impose a significant and overlooked burden in the United States\u2014especially among immigrants, low-income individuals, and other marginalized populations. This perspectives article examines the case of Mr. X, a landscaper in Houston diagnosed with neurocysticercosis, who faced unaffordable drug costs despite the availability of effective, off-patent treatments. Through his story, we explore the broader issue of pricing for commonly and not-so-commonly prescribed antiparasitic medications, highlighting the role of systemic market failures, regulatory hurdles, and restrictive assistance programs in limiting access to care. The consequences of incomplete treatment include long-term disability, public health risks, and deepened health disparities. We propose policy solutions, including reforms to the Orphan Drug Act, expansion of Medicare negotiation powers, and investment in public-interest drug production, to improve affordability and ensure equitable access to essential antiparasitic drugs.<\/jats:p>","DOI":"10.1093\/ofid\/ofaf784","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:54:38Z","timestamp":1768481678000},"source":"Crossref","is-referenced-by-count":0,"title":["Priced Out of Treatment: The Exorbitant Cost of Antiparasitic Drugs in the United States"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2882-1794","authenticated-orcid":false,"given":"Cora","family":"Alperin","sequence":"first","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine (BCM) , Houston, Texas ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-3267","authenticated-orcid":false,"given":"Nhi","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Harris Health , Houston, Texas ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Duffey","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine (BCM) , Houston, Texas ,","place":["USA"]},{"name":"Division of Tropical Medicine, Department of Pediatrics, National School of Tropical Medicine, BCM , Houston, Texas ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0350-8753","authenticated-orcid":false,"given":"Eva H","family":"Clark","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medicine, Baylor College of Medicine (BCM) , Houston, Texas ,","place":["USA"]},{"name":"Division of Tropical Medicine, Department of Pediatrics, National School of Tropical Medicine, BCM , Houston, Texas ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"2026012010271560400_ofaf784-B1","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/pathogens11101212","article-title":"Human neurocysticercosis: an overview","volume":"11","author":"Del Brutto","year":"2022","journal-title":"Pathogens"},{"key":"2026012010271560400_ofaf784-B2","doi-asserted-by":"crossref","first-page":"e1001920","DOI":"10.1371\/journal.pmed.1001920","article-title":"World Health Organization estimates of the Global and Regional Disease Burden of 11 foodborne Parasitic diseases, 2010: a data synthesis","volume":"12","author":"Torgerson","year":"2015","journal-title":"PLoS Med"},{"key":"2026012010271560400_ofaf784-B3","author":"Frontiers in Parasitology"},{"key":"2026012010271560400_ofaf784-B4","doi-asserted-by":"crossref","first-page":"102175","DOI":"10.1016\/j.parint.2020.102175","article-title":"Seroprevalence of toxoplasma gondii in the U.S.: evidence from a representative cross-sectional survey","volume":"79","author":"Owusu-Dommey","year":"2020","journal-title":"Parasitol Int"},{"key":"2026012010271560400_ofaf784-B5","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3201\/eid2807.212221","article-title":"Updated estimates and mapping for prevalence of Chagas disease among adults, United States","volume":"28","author":"Irish","year":"2022","journal-title":"Emerg Infect Dis"},{"key":"2026012010271560400_ofaf784-B6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3201\/eid3109.241700","article-title":"Chagas disease, an endemic disease in the United States","volume":"31","author":"Beatty","year":"2025","journal-title":"Emerg Infect Dis"},{"key":"2026012010271560400_ofaf784-B7","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3201\/eid2106.141324","article-title":"Hospitalization frequency and charges for neurocysticercosis, United States, 2003\u20132012","volume":"21","author":"O\u2019Neal","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2026012010271560400_ofaf784-B8","doi-asserted-by":"crossref","first-page":"e3012","DOI":"10.1371\/journal.pntd.0003012","article-title":"Neglected parasitic infections and poverty in the United States","volume":"8","author":"Hotez","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2026012010271560400_ofaf784-B9","author":"RED BOOK Online [database online]"},{"key":"2026012010271560400_ofaf784-B10","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1093\/cid\/cix1084","article-title":"Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by IDSA and ASTMH","volume":"66","author":"White","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026012010271560400_ofaf784-B11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/14656566.2024.2333372","article-title":"Current drug strategies for the treatment and control of schistosomiasis","volume":"25","author":"Villamizar-Monsalve","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"2026012010271560400_ofaf784-B12","author":"Centers for Disease Control and Prevention"},{"key":"2026012010271560400_ofaf784-B13","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1161\/CIR.0000000000000599","article-title":"Chagas cardiomyopathy: an update of current clinical knowledge and management","volume":"138","author":"Nunes","year":"2018","journal-title":"Circulation"},{"key":"2026012010271560400_ofaf784-B14","author":"Centers for Disease Control and Prevention"},{"key":"2026012010271560400_ofaf784-B15","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ajg.2016.126","article-title":"ACG clinical guideline: acute diarrheal infections in adults","volume":"111","author":"Riddle","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2026012010271560400_ofaf784-B16","first-page":"1","article-title":"The FDA amendments act and generic drug entry","volume":"9","author":"Garthwaite","year":"2017","journal-title":"Am Econ J Econ Policy"},{"key":"2026012010271560400_ofaf784-B17","volume-title":"The Orphan Drug Act: background and impacts","author":"Institute of Medicine (US) Forum on Drug Discovery","year":"2017"},{"key":"2026012010271560400_ofaf784-B18","first-page":"585","article-title":"Martin Shkreli and the pyrimethamine pricing scandal","volume":"315","author":"Greene","year":"2016","journal-title":"JAMA"},{"key":"2026012010271560400_ofaf784-B19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.15585\/mmwr.mm6729a3","article-title":"Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011\u20132018","volume":"67","author":"Herwaldt","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/1\/ofaf784\/66475352\/ofaf784.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/1\/ofaf784\/66475352\/ofaf784.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:27:29Z","timestamp":1768922849000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf784\/8431476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,26]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf784","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,26]]},"article-number":"ofaf784"}}